Students Developing Portable Device to Quickly Detect Bacterial Infections
By LabMedica International staff writers Posted on 08 Nov 2016 |
Image: A new device capable of quickly diagnosing bacterial infections could help doctors improve the way they prescribe treatment for patients (Photo courtesy of the University of Sheffield).
The new diagnostic tool, which uses genetically engineered bacteria to detect bacterial infections in blood samples, would lead to more informed decisions that would reduce the number of patients with viral infections being prescribed antibiotics, thus reducing unnecessary treatments and helping to tackle antibiotic resistance.
The device is being developed by the University of Sheffield’s (Sheffield, UK) team of students who participated in this year’s “International Genetically Engineered Machine Competition” – iGEM 2016 (October 27-31; Boston, MA, USA) in the field of synthetic biology. The team consists of students from a range of science, engineering, and medicine disciplines.
They hope the device could be used after GP surgeries to potentially help prevent complications from sepsis, or in walk-in clinics to enable patients with flu-like symptoms to have a small blood sample tested and be promptly told whether they have a bacterial or non-bacterial infection and be treated accordingly.
The tool distinguishes between bacterial and viral infection by detecting levels of the protein lipocalin-2, which is produced in high levels by immune system cells in response to bacterial infections. Bacteria produce siderophores that scavenge iron (as Fe3+) from host blood. In response, the immune system produces lipocalin-2, which sequesters siderophores. Lipocalin-2 levels can increase 5-fold during a bacterial infection. The device detects lipocalin-2 levels using genetically engineered bacteria that report a fluorescent signal inversely correlated to lipocalin-2 levels (via repression of GFP, the fluorescent reporter protein).
Therefore, patient blood with bacterial infection results in a weak GFP signal, in contrast to a strong signal without bacterial infection. The portable device, which includes a shoebox size fluorometer, potentially has the capability of rapidly determining the presence of any bacterial infection.
“Antibiotic resistance is a huge problem and this is why we chose to base our project on it,” said Saylee Jangam, a Sheffield student on the iGEM team, “We may not be able to reverse it, but with our device, we could potentially slow it down. What’s even more interesting is that we are using genetically engineered bacteria to detect the presence of bacterial infections in blood – that’s right – using bacteria to detect bacteria.”
Related Links:
University of Sheffield
The device is being developed by the University of Sheffield’s (Sheffield, UK) team of students who participated in this year’s “International Genetically Engineered Machine Competition” – iGEM 2016 (October 27-31; Boston, MA, USA) in the field of synthetic biology. The team consists of students from a range of science, engineering, and medicine disciplines.
They hope the device could be used after GP surgeries to potentially help prevent complications from sepsis, or in walk-in clinics to enable patients with flu-like symptoms to have a small blood sample tested and be promptly told whether they have a bacterial or non-bacterial infection and be treated accordingly.
The tool distinguishes between bacterial and viral infection by detecting levels of the protein lipocalin-2, which is produced in high levels by immune system cells in response to bacterial infections. Bacteria produce siderophores that scavenge iron (as Fe3+) from host blood. In response, the immune system produces lipocalin-2, which sequesters siderophores. Lipocalin-2 levels can increase 5-fold during a bacterial infection. The device detects lipocalin-2 levels using genetically engineered bacteria that report a fluorescent signal inversely correlated to lipocalin-2 levels (via repression of GFP, the fluorescent reporter protein).
Therefore, patient blood with bacterial infection results in a weak GFP signal, in contrast to a strong signal without bacterial infection. The portable device, which includes a shoebox size fluorometer, potentially has the capability of rapidly determining the presence of any bacterial infection.
“Antibiotic resistance is a huge problem and this is why we chose to base our project on it,” said Saylee Jangam, a Sheffield student on the iGEM team, “We may not be able to reverse it, but with our device, we could potentially slow it down. What’s even more interesting is that we are using genetically engineered bacteria to detect the presence of bacterial infections in blood – that’s right – using bacteria to detect bacteria.”
Related Links:
University of Sheffield
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia